Quintiles is gearing up to expand its offerings in Russia as part of a continuing international growth plan by the company that already is the world’s largest provider of life science services.

The company said Friday it would partner with the Russian Venture Company Biofund to expand clinicial development services in the Russian Federation.

“Quintiles and RVC Biofund anticipate announcing plans for specific joint ventures in the near future,” the companies said in a joint statement.

The Russian expansion is the latest in a series of moves made by Quintiles over the past several months to broaden its international footprint. In addition to several acquisitions, Quintiles recently announced plans to add as many as 500 jobs in China and to beef up efforts in the Middle East and Africa.

Quintiles already operates in Russia, maintaining a presence there since 1996. Its main office is located in Moscow.

“With a population of almost 140 million, Russia is under-represented in terms of clinical development activity and over-represented in term of unmet medical needs,” said Ben Cons, Global Vice President for Quintiles Corporate Development, in a statement. “Quintiles’ goal is to address both of those issues in partnership with RVC Biofund, which has experience in starting businesses in Russia and capital to invest in the biopharma sector.”

The companies will look to form services companies, said Egor Beketov, chief executive officer of the Biofund.

“This partnership will help create high-technology services companies within the Russian Federation to advance biopharma, using RVC Biofund venture capital investments. With Quintiles, RVC Biofund gets a partner with the global resources and expertise to further expand development capabilities in Russia.”

Quintiles opened a new headquarters in the U.K. last fall and its first data center in India in January 2011.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.